Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein

Hematological malignancies harboring various ABL1 fusions are expected to be sensitive to tyrosine kinase inhibitors (TKIs), similar to those with BCR-ABL1. However, SEPT9-ABL1 exhibits TKI resistance both in vitro and in vivo. SEPT9-ABL1 has the same ABL1 region as seen in BCR-ABL1 but no point mut...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neoplasia
Main Authors: Kawai, Hidetsugu, Matsushita, Hiromichi, Suzuki, Rikio, Kitamura, Yuka, Ogawa, Yoshiaki, Kawada, Hiroshi, Ando, Kiyoshi
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2019
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6611969/
https://ncbi.nlm.nih.gov/pubmed/31276931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2019.06.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados